Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7099)
All Articles published online
|
Publishing Process of This Article
|
Nov 14, 2013 (publication date) through Apr 19, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: |
Trifan A, Girleanu I, Cojocariu C, Sfarti C, Singeap AM, Dorobat C, Grigore L, Stanciu C. Pseudomembranous colitis associated with a triple therapy for |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v19/i42/7476.htm |
| Number | Citing Articles |
| 1 |
Kiyofumi Wanibuchi, Kouichi Hosoda, Masato Ihara, Kentaro Tajiri, Yuki Sakai, Hisashi Masui, Takashi Takahashi, Yoshikazu Hirai, Hirofumi Shimomura. Indene Compounds Synthetically Derived from Vitamin D Have Selective Antibacterial Action on Helicobacter pylori. Lipids 2018; 53(4): 393 doi: 10.1002/lipd.12043
|
| 2 |
Bo Tang, Li Tang, Cheng Huang, Chuan Tian, Ling Chen, Zhijun He, Guodong Yang, Luo Zuo, Guoce Zhao, En Liu, Sumin Wang, Hui Lin, Jialin He, Shiming Yang. The Effect of Probiotics Supplementation on Gut Microbiota After Helicobacter pylori Eradication: A Multicenter Randomized Controlled Trial. Infectious Diseases and Therapy 2021; 10(1): 317 doi: 10.1007/s40121-020-00372-9
|
| 3 |
Manuel Castro-Fernández, Alberto Marqués-Ruiz, Sergio Cámara-Baena, Lourdes Grande-Santamaría. Infección por Clostridium difficile tras tratamiento erradicador de Helicobacter pylori con cuádruple terapia con bismuto (Pylera®). Gastroenterología y Hepatología 2019; 42(7): 459 doi: 10.1016/j.gastrohep.2019.01.012
|
| 4 |
Kiyofumi Wanibuchi, Hisashi Masui, Takashi Takahashi, Hirofumi Shimomura. Gastritis - New Approaches and Treatments. 2019; doi: 10.5772/intechopen.86165
|
| 5 |
Mārcis Leja, Uga Dumpis. What Would the Screen-and-Treat Strategy for Helicobacter pylori Mean in Terms of Antibiotic Consumption?. Digestive Diseases and Sciences 2020; 65(6): 1632 doi: 10.1007/s10620-019-05893-z
|
| 6 |
Toshiki Horii, Sho Suzuki, Chika Takano, Hitoshi Shibuya, Ryoji Ichijima, Chika Kusano, Hisatomo Ikehara, Takuji Gotoda. Lower impact of vonoprazan–amoxicillin dual therapy on gut microbiota forHelicobacter pylorieradication. Journal of Gastroenterology and Hepatology 2021; 36(12): 3314 doi: 10.1111/jgh.15572
|
| 7 |
Ping‐I Hsu, Chao‐Yu Pan, John Y. Kao, Feng‐Woei Tsay, Nan‐Jing Peng, Sung‐Shuo Kao, Huay‐Min Wang, Tzung‐Jiun Tsai, Deng‐Chyang Wu, Chien‐Lin Chen, Kuo‐Wang Tsai. Helicobacter pylori eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of Proteobacteria and decreased relative abundances of Bacteroidetes and Actinobacteria. Helicobacter 2018; 23(4) doi: 10.1111/hel.12498
|
| 8 |
Bumjo Oh, Bong‐Soo Kim, Ji Won Kim, Jong Seung Kim, Seong‐Joon Koh, Byeong Gwan Kim, Kook Lae Lee, Jongsik Chun. The Effect of Probiotics on Gut Microbiota during the Helicobacter pylori Eradication: Randomized Controlled Trial. Helicobacter 2016; 21(3): 165 doi: 10.1111/hel.12270
|
| 9 |
P. Malfertheiner, J. C. Delchier. Letter: bismuth quadruple therapy with Pylera for Helicobacter pylori infection – authors’ reply. Alimentary Pharmacology & Therapeutics 2014; 40(6): 736 doi: 10.1111/apt.12909
|
| 10 |
Amoxicillin/clarithromycin/pantoprazole. Reactions Weekly 2014; 1521(1): 27 doi: 10.1007/s40278-014-3832-8
|
| 11 |
Manuel Castro-Fernández, Alberto Marqués-Ruiz, Sergio Cámara-Baena, Lourdes Grande-Santamaría. Clostridium difficile infection associated with bismuth-based quadruple therapy (Pylera®) for Helicobacter pylori eradication. Gastroenterología y Hepatología (English Edition) 2019; 42(7): 459 doi: 10.1016/j.gastre.2019.01.021
|
| 12 |
Masoud Keikha, Hossein Kamali. The impact of Saccharomyces boulardii adjuvant supplementation on alternation of gut microbiota after H. pylori eradication; a metagenomics analysis. Gene Reports 2022; 26: 101499 doi: 10.1016/j.genrep.2022.101499
|
| 13 |
Ping‐I Hsu, Chao‐Yu Pan, John Y Kao, Feng‐Woei Tsay, Nan‐Jing Peng, Sung‐Shuo Kao, Yan‐Hua Chen, Tzung‐Jiun Tsai, Deng‐Chyang Wu, Kuo‐Wang Tsai. Short‐term and long‐term impacts of Helicobacter pylori eradication with reverse hybrid therapy on the gut microbiota. Journal of Gastroenterology and Hepatology 2019; 34(11): 1968 doi: 10.1111/jgh.14736
|
| 14 |
Hirofumi Shimomura, Kiyofumi Wanibuchi, Kouichi Hosoda, Avarzed Amgalanbaatar, Hisashi Masui, Takashi Takahashi, Yoshikazu Hirai. Unique responses of Helicobacter pylori to exogenous hydrophobic compounds. Chemistry and Physics of Lipids 2020; 229: 104908 doi: 10.1016/j.chemphyslip.2020.104908
|
| 15 |
Khitam Muhsen, Wasef Na'amnih, Amos Adler, Yehuda Carmeli, Dani Cohen. Clostridiumdifficile‐associated disease and Helicobacter pylori seroprevalence: A case‐control study. Helicobacter 2020; 25(1) doi: 10.1111/hel.12668
|
| 16 |
Olga Sjomina, Alise Lielause, Aiga Rūdule, Reinis Vangravs, Sergejs Paršutins, Inese Poļaka, Ilva Daugule, Ilmārs Stonāns, Jin Young Park, Mārcis Leja. Randomised clinical trial: comparison of efficacy and adverse effects of a standard triple clarithromycin-containing regimen with high-dose amoxicillin and bismuth therapy in Helicobacter pylori eradication. European Journal of Cancer Prevention 2022; 31(4): 333 doi: 10.1097/CEJ.0000000000000718
|
| 17 |
Qunqun Ye, Xiaona Shao, Ruiwei Shen, Dawei Chen, Jianwei Shen. Changes in the human gut microbiota composition caused by Helicobacter pylori eradication therapy: A systematic review and meta‐analysis. Helicobacter 2020; 25(4) doi: 10.1111/hel.12713
|
| 18 |
Wen Gao, Ying Xu, Jianxiang Liu, Xiaolei Wang, Xinhong Dong, Guigen Teng, Binbin Liu, Jinpei Dong, Chaoyi Ge, Hui Ye, Xuezhi Zhang, Hong Cheng. A real‐world exploratory study on the feasibility of vonoprazan and tetracycline dual therapy for the treatment of Helicobacter pylori infection in special populations with penicillin allergy or failed in previous amoxicillin‐containing therapies. Helicobacter 2023; 28(2) doi: 10.1111/hel.12947
|
| 19 |
Paulius Jonaitis, Juozas Kupcinskas, Javier P. Gisbert, Laimas Jonaitis. Helicobacter pylori Eradication Treatment in Older Patients. Drugs & Aging 2024; 41(2): 141 doi: 10.1007/s40266-023-01090-w
|
| 20 |
Henrik Gregersen, Trung Do, Ida Bruun Kristensen, Ulf Christian Frølund, Niels Frost Andersen, Lene Kongsgaard Nielsen, Christen Lykkegaard Andersen, Tobias Wirenfeldt Klausen, Annette Juul Vangsted, Niels Abildgaard. A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma. Experimental Hematology & Oncology 2018; 7(1) doi: 10.1186/s40164-018-0110-0
|
| 21 |
Ayala G. Carl, Lawrence D. Harris, Mu Feng, Lars U. Nordstrøm, Gary J. Gerfen, Gary B. Evans, Alexey Silakov, Steven C. Almo, Tyler L. Grove. Narrow-Spectrum Antibiotic Targeting of the Radical SAM Enzyme MqnE in Menaquinone Biosynthesis. Biochemistry 2020; 59(27): 2562 doi: 10.1021/acs.biochem.0c00070
|
| 22 |
Hoon Gil Jo, Yong Sung Kim. Helicobacter pylori Eradication Therapy-associated Diarrhea. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2021; 21(3): 203 doi: 10.7704/kjhugr.2021.0037
|
| 23 |
Saccharomyces boulardii Combined With Quadruple Therapy for Helicobacter pylori Eradication Decreased the Duration and Severity of Diarrhea: A Multi-Center Prospective Randomized Controlled Trial. Frontiers in Medicine 2021; 8 doi: 10.3389/fmed.2021.776955
|
| 24 |
Kiyofumi Wanibuchi, Motoki Takezawa, Kouichi Hosoda, Avarzed Amgalanbaatar, Kentaro Tajiri, Yuki Koizumi, Sakura Niitsu, Hisashi Masui, Yuki Sakai, Mitsuru Shoji, Takashi Takahashi, Yoshikazu Hirai, Hirofumi Shimomura. Antibacterial effect of indene on Helicobacter pylori correlates with specific interaction between its compound and dimyristoyl-phosphatidylethanolamine. Chemistry and Physics of Lipids 2020; 227: 104871 doi: 10.1016/j.chemphyslip.2020.104871
|
| 25 |
Takahito Nei, Jun Hagiwara, Toru Takiguchi, Shoji Yokobori, Kim Shiei, Hiroyuki Yokota, Mitsutoshi Senoh, Haru Kato. Fatal fulminant Clostridioides difficile colitis caused by Helicobacter pylori eradication therapy; a case report. Journal of Infection and Chemotherapy 2020; 26(3): 305 doi: 10.1016/j.jiac.2019.10.021
|
| 26 |
Shria Kumar, David C. Metz, David E. Kaplan, David S. Goldberg. Treatment of Helicobacter pylori Is Not Associated With Future Clostridium difficile Infection. American Journal of Gastroenterology 2020; 115(5): 716 doi: 10.14309/ajg.0000000000000626
|
| 27 |
Kiyofumi Wanibuchi, Kouichi Hosoda, Avarzed Amgalanbaatar, Masato Ihara, Motoki Takezawa, Yuki Sakai, Hisashi Masui, Mitsuru Shoji, Shunji Hayashi, Hirofumi Shimomura. Aspects for development of novel antibacterial medicines using a vitamin D3 decomposition product in Helicobacter pylori infection. The Journal of Antibiotics 2023; 76(11): 665 doi: 10.1038/s41429-023-00651-w
|